FDA Warning Letter calls explicitly for CAPA
Recommendation
15/16 October 2024
Understanding the Importance of GMP
Again, the U.S. Food and Drug Administration FDA has issued a Warning Letter mainly focussing on Data Integrity.
This new Warning Letter contains GMP observations in four areas:
- Incomplete data in laboratory records;
- Inappropriate controls over computer systems;
- Inadequate written procedures for production and process controls;
- Failure to follow certain written procedures.
In the description of the observations data integrity deficiencies become obvious which are circumstantiated in a detailed way.
But what is interesting with this one is that FDA clearly proposes some necessary actions and asks for appropriate corrective and preventive actions (CAPA). This description of the corrective actions seems unusual but appears to be part of a trend in Warning Letters:
- A "comprehensive investigation into the extent of the inaccuracies in data records and reporting", including "interviews of current and former employees … by a qualified third party;"
- A "current risk assessment of the potential effects of the observed failures on the quality of your drugs," including the risk to patients;
- A "management strategy for your firm that includes the details of your global corrective action and preventive action plan," including "measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, … drug application actions, and enhanced complaint monitoring."
A reason for this might be that FDA is concerned with the company's first response. The proposed actions of the company were "insufficient to correct the broad data manipulation and deletion problems observed at your facility and to prevent their recurrence." FDA also asks that in the response "an assessment of the effectiveness of these newly implemented system controls" should have been provided.
Related GMP News
18.09.2024Lack of GMP Training and related Documentation: What Deviations can be found in FDA Warning Letters?
04.09.2024Switzerland: Changes for the Qualification of QPs (Responsible Person; RP in Switzerland)
04.09.2024Insufficient Root Cause Analysis leads to FDA Warning Letter
28.08.2024Switzerland to implement Measures to combat Shortages of Medicines
26.06.202410 points on how the FDA's CDER monitors the Quality of Medicinal Products
08.05.2024EMA Plans for the next three Years